|
1 Interpretation of the Complete Blood Count |
|
|
1 | (14) |
|
|
|
|
|
|
|
|
|
Red Cell Distribution Width |
|
|
1 | (1) |
|
|
|
1 | (1) |
|
|
|
2 | (1) |
|
|
|
2 | (1) |
|
Role of MCV, RDW and Reticulocyte Count in Evaluating Anemia |
|
|
3 | (3) |
|
|
|
6 | (1) |
|
|
|
7 | (2) |
|
|
|
9 | (1) |
|
|
|
10 | (1) |
|
|
|
11 | (1) |
|
|
|
11 | (1) |
|
|
|
11 | (1) |
|
|
|
12 | (1) |
|
|
|
12 | (1) |
|
Basophilic Stippling (Aggregated Ribosomes) |
|
|
12 | (1) |
|
|
|
13 | (1) |
|
Siderocytes (Nonhemoglobin Iron) |
|
|
13 | (1) |
|
Cabot's Rings (Nuclear Remnants) |
|
|
13 | (1) |
|
|
|
13 | (1) |
|
|
|
13 | (1) |
|
|
|
13 | (1) |
|
Spiculated/Crenated Cells |
|
|
13 | (1) |
|
|
|
13 | (2) |
|
2 Clinical Approach to a Child with Anemia |
|
|
15 | (6) |
|
|
|
|
|
|
|
Approach to a Child with Anemia |
|
|
15 | (1) |
|
|
|
15 | (1) |
|
|
|
15 | (1) |
|
Clinical Judgment of Anemia |
|
|
15 | (1) |
|
|
|
15 | (1) |
|
What is the Type and Cause of Anemia? |
|
|
16 | (5) |
|
3 Laboratory Evaluation of a Patient with Anemia |
|
|
21 | (10) |
|
|
|
|
|
|
|
|
|
Mechanisms and Pathophysiology of Anemia |
|
|
21 | (7) |
|
Signs of Accelerated Erythropoiesis |
|
|
28 | (1) |
|
Signs of Accelerated RBC Destruction |
|
|
29 | (1) |
|
Investigations for Hemolytic Anemia |
|
|
29 | (2) |
|
|
|
31 | (3) |
|
|
|
|
|
|
|
|
|
|
|
31 | (1) |
|
|
|
31 | (1) |
|
|
|
31 | (1) |
|
|
|
32 | (1) |
|
|
|
32 | (2) |
|
|
|
34 | (7) |
|
|
|
|
|
|
|
|
|
|
|
34 | (1) |
|
Normal Hematological Values in the Neonatal Period |
|
|
34 | (2) |
|
|
|
36 | (2) |
|
Diagnostic Approach to Anemia in a Newborn |
|
|
38 | (1) |
|
Treatment of Anemia in Newborn |
|
|
38 | (3) |
|
|
|
41 | (12) |
|
|
|
|
|
|
|
|
|
|
|
41 | (1) |
|
|
|
41 | (1) |
|
|
|
42 | (1) |
|
|
|
43 | (1) |
|
Consequences of Iron Deficiency |
|
|
44 | (1) |
|
Assessment of Iron Status and Screening for Anemia |
|
|
44 | (2) |
|
|
|
46 | (1) |
|
Prevention of Nutritional Anemia |
|
|
47 | (2) |
|
Macrocytic-Megaloblastic Anemia |
|
|
49 | (4) |
|
7 National Nutritional Anemia Control Program |
|
|
53 | (4) |
|
|
|
|
|
|
|
National Nutritional Anemia Prophylaxis Program |
|
|
53 | (1) |
|
Evaluation of Iron Supplementation Program |
|
|
53 | (1) |
|
National Nutritional Anemia Control Program |
|
|
53 | (4) |
|
8 Aplastic Anemia: Current Issues in Diagnosis and Management |
|
|
57 | (12) |
|
|
|
|
|
|
|
57 | (1) |
|
|
|
57 | (1) |
|
|
|
57 | (2) |
|
Etiology of Aplastic Anemia: Recognized Causes |
|
|
59 | (4) |
|
Management of Aplastic Anemia |
|
|
63 | (1) |
|
|
|
64 | (5) |
|
Appendix 1 Practical Issues with Immunosuppressive Therapy in Aplastic Anemia |
|
|
66 | (3) |
|
9 Approach to the Diagnosis of Hemolytic Disorders |
|
|
69 | (6) |
|
|
|
|
|
|
|
History and Physical Examination |
|
|
69 | (2) |
|
Specific Tests to Establish the Cause of Hemolysis |
|
|
71 | (1) |
|
Salient Laboratory Features of Common Disorders Associated with Hemolytic Anemia |
|
|
71 | (4) |
|
10 Management of β-Thalassemia Major |
|
|
75 | (10) |
|
|
|
|
|
|
|
|
|
75 | (3) |
|
|
|
78 | (1) |
|
|
|
78 | (1) |
|
|
|
78 | (1) |
|
|
|
78 | (2) |
|
Deferiprone (Ferripox, Kelfer, L1) Therapy |
|
|
80 | (1) |
|
|
|
81 | (1) |
|
Bone Marrow Transplantation |
|
|
82 | (1) |
|
Cord Blood Transplantation |
|
|
82 | (1) |
|
Alternative Therapies in Thalassemia |
|
|
83 | (1) |
|
|
|
83 | (2) |
|
11 Hemolytic Anemia (Other than Thalassemia) Management |
|
|
85 | (5) |
|
|
|
Hereditary Hemolytic Anemias (Intracorpuscular Defect) |
|
|
85 | (2) |
|
Acquired Hemolytic Anemias |
|
|
87 | (2) |
|
|
|
89 | (1) |
|
|
|
89 | (1) |
|
Paroxysmal Nocturnal Hemoglobinuria |
|
|
89 | (1) |
|
|
|
90 | (7) |
|
|
|
|
|
|
|
|
|
Normal Upper Thrombocyte Levels in Childhood |
|
|
90 | (1) |
|
Physiology of Platelet Production |
|
|
90 | (1) |
|
|
|
90 | (1) |
|
|
|
90 | (1) |
|
|
|
91 | (1) |
|
|
|
91 | (1) |
|
|
|
92 | (1) |
|
|
|
93 | (1) |
|
|
|
93 | (1) |
|
|
|
94 | (1) |
|
Gastrointestinal Disease without Infection |
|
|
94 | (1) |
|
|
|
94 | (1) |
|
|
|
94 | (1) |
|
|
|
94 | (1) |
|
|
|
94 | (1) |
|
|
|
94 | (1) |
|
Indications for Prophylaxis |
|
|
95 | (1) |
|
Primary Familial Thrombocytosis |
|
|
95 | (2) |
|
13 Hemostasis: Developmental Aspects and Rare Congenital Bleeding Disorders |
|
|
97 | (18) |
|
|
|
|
|
|
|
|
|
97 | (2) |
|
|
|
99 | (1) |
|
|
|
100 | (1) |
|
|
|
100 | (1) |
|
Protein C/Protein S Anticoagulant Pathway |
|
|
100 | (1) |
|
|
|
100 | (1) |
|
|
|
100 | (1) |
|
|
|
100 | (1) |
|
Causes of Neonatal Bleeding (Deranged Hemostasis) |
|
|
101 | (1) |
|
|
|
101 | (1) |
|
|
|
102 | (1) |
|
|
|
102 | (1) |
|
Deficiencies of the Intrinsic Pathway Contact Activating System |
|
|
102 | (1) |
|
|
|
103 | (1) |
|
Factor X (Stuart-Prower Factor) Deficiency |
|
|
104 | (1) |
|
|
|
105 | (1) |
|
|
|
106 | (1) |
|
Deficiencies of the Common Pathway Prothrombin Deficiency |
|
|
106 | (1) |
|
|
|
107 | (2) |
|
|
|
109 | (1) |
|
Congenital Factor XIII Deficiency |
|
|
110 | (1) |
|
Acquired Coagulation Disorders |
|
|
111 | (1) |
|
Vitamin K Deficiency Bleeding |
|
|
112 | (3) |
|
14 von Willebrand's Disease |
|
|
115 | (5) |
|
|
|
|
|
|
|
|
|
|
|
115 | (1) |
|
Laboratory Diagnosis and Monitoring |
|
|
115 | (2) |
|
von Willebrand's Disease Classification |
|
|
117 | (3) |
|
15 Management of Hemophilia |
|
|
120 | (5) |
|
|
|
Products for Replacement Therapy |
|
|
120 | (1) |
|
Nonfactor Pharmacological Agents |
|
|
121 | (1) |
|
Management of Acute Bleeds |
|
|
121 | (1) |
|
Management of Chronic Complications |
|
|
122 | (1) |
|
Physical Therapy and Rehabilitation |
|
|
122 | (1) |
|
|
|
123 | (1) |
|
Management of Patients with Inhibitors |
|
|
123 | (1) |
|
Carrier Detection and Antenatal Diagnosis |
|
|
124 | (1) |
|
|
|
124 | (1) |
|
16 Thrombocytopenia Other than ITP and Thrombasthenia |
|
|
125 | (5) |
|
|
|
|
|
125 | (1) |
|
Drug-Induced Thrombocytopenia |
|
|
125 | (2) |
|
Decreased or Absent Megakaryocytes in the Marrow |
|
|
127 | (3) |
|
17 Immune Thrombocytopenia: Diagnosis and Management |
|
|
130 | (14) |
|
|
|
|
|
|
|
What are Various Types of ITP? |
|
|
130 | (1) |
|
|
|
131 | (1) |
|
|
|
131 | (1) |
|
Important Factors in Diagnosis |
|
|
131 | (3) |
|
|
|
134 | (1) |
|
Evaluation of Patients with Persistent/Early Refractory ITP |
|
|
134 | (1) |
|
|
|
134 | (3) |
|
|
|
137 | (1) |
|
Intravenous Immunoglobulin |
|
|
138 | (1) |
|
|
|
138 | (1) |
|
|
|
139 | (1) |
|
Thrombopoietin-Receptor Agonists: Romiplostim and Eltrombopag |
|
|
139 | (1) |
|
Dapsone (Diamino-Diphenyl Sulfone) |
|
|
140 | (1) |
|
|
|
140 | (1) |
|
Splenectomy in Chronic ITP |
|
|
140 | (1) |
|
Are Immunosuppressant Drugs Useful in Chronic ITP? |
|
|
141 | (3) |
|
18 Vitamin K Deficiency Bleeding |
|
|
144 | (4) |
|
|
|
Definition and Inclusion Criteria |
|
|
144 | (1) |
|
|
|
145 | (1) |
|
|
|
145 | (1) |
|
|
|
145 | (1) |
|
|
|
146 | (1) |
|
|
|
146 | (1) |
|
|
|
146 | (2) |
|
19 Neonatal Thrombocytopenia |
|
|
148 | (5) |
|
|
|
|
|
|
|
Neonatal Autoimmune Thrombocytopenia |
|
|
150 | (1) |
|
Nonimmune Thrombocytopenia |
|
|
151 | (1) |
|
Hereditary Thrombocytopenia |
|
|
151 | (2) |
|
20 Hypercoagulable Disease in Children and its Diagnostic Approach |
|
|
153 | (3) |
|
|
|
Acquired Hypercoagulable State |
|
|
153 | (1) |
|
Inherited Hypercoagulable States |
|
|
153 | (3) |
|
21 Antithrombotic Therapy in Pediatrics |
|
|
156 | (9) |
|
|
|
|
|
|
|
|
|
156 | (1) |
|
Mechanism of Action and Pharmacology |
|
|
156 | (1) |
|
Dosing and Administration |
|
|
157 | (1) |
|
|
|
157 | (1) |
|
|
|
157 | (1) |
|
Adverse Effects, Reversal of Action and Antidote of UHF |
|
|
157 | (1) |
|
Heparin-induced Thrombocytopenia |
|
|
158 | (1) |
|
Low Molecular Weight Heparin |
|
|
158 | (1) |
|
|
|
158 | (1) |
|
|
|
158 | (1) |
|
|
|
158 | (1) |
|
|
|
158 | (1) |
|
|
|
159 | (1) |
|
|
|
159 | (1) |
|
|
|
159 | (1) |
|
|
|
159 | (1) |
|
|
|
159 | (1) |
|
|
|
160 | (1) |
|
|
|
160 | (1) |
|
|
|
160 | (1) |
|
Dosing in Thrombolytic Therapy |
|
|
161 | (1) |
|
|
|
162 | (1) |
|
|
|
162 | (1) |
|
Contraindications of Thrombolytic Therapy |
|
|
162 | (1) |
|
Treatment of Pediatric Venous Thromboembolism in Children |
|
|
162 | (1) |
|
Treatment of Kawasaki Disease in Children |
|
|
163 | (1) |
|
Children Undergoing Fontan Procedure |
|
|
163 | (1) |
|
Children with Homozygous Protein C and S Deficiency |
|
|
163 | (2) |
|
|
|
165 | (13) |
|
|
|
|
|
|
|
|
|
|
|
165 | (3) |
|
|
|
168 | (1) |
|
|
|
169 | (2) |
|
|
|
171 | (1) |
|
|
|
172 | (6) |
|
23 Polycythemia in Newborn |
|
|
178 | (3) |
|
|
|
|
|
|
|
|
|
178 | (1) |
|
Causes of Neonatal Polycythemia |
|
|
178 | (1) |
|
|
|
178 | (1) |
|
|
|
179 | (1) |
|
Complications of Exchange Transfusion |
|
|
180 | (1) |
|
24 Blood Component Therapy |
|
|
181 | (18) |
|
|
|
|
|
|
|
|
|
The Appropriate Use of Blood and Blood Products |
|
|
181 | (1) |
|
|
|
182 | (1) |
|
|
|
182 | (4) |
|
Special Considerations for Newborns |
|
|
186 | (1) |
|
|
|
187 | (2) |
|
Special Considerations for Newborns |
|
|
189 | (1) |
|
|
|
189 | (3) |
|
|
|
192 | (1) |
|
|
|
193 | (1) |
|
|
|
193 | (1) |
|
|
|
194 | (1) |
|
Discussion on Special Topics |
|
|
194 | (1) |
|
Component and Procedure Specification |
|
|
195 | (4) |
|
25 Transfusion Transmitted Infections |
|
|
199 | (9) |
|
|
|
|
|
|
|
199 | (2) |
|
|
|
201 | (1) |
|
|
|
202 | (1) |
|
|
|
202 | (1) |
|
|
|
202 | (1) |
|
Hepatitis GB Virus C/Hepatitis G Virus |
|
|
202 | (1) |
|
|
|
202 | (1) |
|
Human Immunodeficiency Virus Types 1 and 2 (HIV1 and HIV2) |
|
|
202 | (1) |
|
Human T-Lymphotropic Virus I and II |
|
|
203 | (1) |
|
|
|
203 | (1) |
|
|
|
204 | (1) |
|
|
|
204 | (1) |
|
|
|
204 | (1) |
|
Creutzfeldt-Jakob Disease |
|
|
205 | (1) |
|
Bacterial Contamination of Blood |
|
|
205 | (1) |
|
Rarely Transmitted Parasites |
|
|
205 | (1) |
|
Inactivation of Viruses in Blood Products |
|
|
205 | (1) |
|
|
|
205 | (3) |
|
26 Supportive Care in Children with Cancer |
|
|
208 | (24) |
|
|
|
|
|
|
|
Who Provides Supportive Care? |
|
|
208 | (1) |
|
Prevention and Management of Infection in Immunocompromised Hosts |
|
|
208 | (1) |
|
|
|
209 | (1) |
|
Febrile Splenectomized Patients |
|
|
210 | (1) |
|
|
|
211 | (1) |
|
|
|
212 | (3) |
|
|
|
215 | (2) |
|
|
|
217 | (1) |
|
Hematopoietic Growth Factors: Basic Biology of Growth Factors |
|
|
218 | (3) |
|
Prevention of Organ Toxicity |
|
|
221 | (1) |
|
|
|
222 | (2) |
|
General Guidelines for Management of Pain in Oncology Patients |
|
|
224 | (1) |
|
Management of Nausea and Vomiting |
|
|
225 | (2) |
|
|
|
227 | (2) |
|
|
|
229 | (1) |
|
Psychosocial Support and End-of-Life Care |
|
|
230 | (2) |
|
27 Hematological Manifestations of Systemic Diseases |
|
|
232 | (15) |
|
|
|
|
|
|
|
|
|
232 | (1) |
|
Connective Tissue Disorders |
|
|
233 | (1) |
|
|
|
233 | (2) |
|
Viral Illnesses with Marked Hematologic Sequel |
|
|
235 | (3) |
|
Hematologic Changes Associated with Specific Infections in the Tropics |
|
|
238 | (2) |
|
Hyper-reactive Malarial Splenomegaly Syndrome |
|
|
240 | (1) |
|
|
|
241 | (6) |
|
28 Disseminated Intravascular Coagulation |
|
|
247 | (12) |
|
|
|
|
|
|
|
|
|
|
|
247 | (1) |
|
|
|
248 | (2) |
|
|
|
250 | (1) |
|
|
|
250 | (1) |
|
|
|
251 | (1) |
|
|
|
251 | (2) |
|
|
|
253 | (1) |
|
|
|
254 | (1) |
|
|
|
254 | (1) |
|
Management (Acute Disseminated Intravascular Coagulation) |
|
|
254 | (5) |
|
29 Disorders of White Blood Cells |
|
|
259 | (3) |
|
|
|
|
|
259 | (1) |
|
|
|
260 | (1) |
|
|
|
260 | (1) |
|
|
|
260 | (1) |
|
|
|
260 | (1) |
|
|
|
260 | (1) |
|
|
|
260 | (1) |
|
|
|
261 | (1) |
|
30 Hematological Changes in HIV Infection |
|
|
262 | (4) |
|
|
|
Hematological Changes Seen in HIV |
|
|
262 | (1) |
|
|
|
262 | (1) |
|
|
|
262 | (1) |
|
|
|
263 | (1) |
|
|
|
263 | (1) |
|
|
|
263 | (1) |
|
Coagulation Disorders in HIV |
|
|
264 | (1) |
|
Hematological Malignancies in HIV |
|
|
264 | (1) |
|
|
|
264 | (2) |
|
31 Approach to a Patient with Splenomegaly and Lymphadenopathy |
|
|
266 | (6) |
|
|
|
|
|
32 Myelodysplastic Syndrome in Children |
|
|
272 | (9) |
|
|
|
|
|
|
|
272 | (1) |
|
Current Approach to the Classification of Childhood MDS |
|
|
272 | (1) |
|
Primary and Secondary MDS |
|
|
273 | (1) |
|
|
|
273 | (1) |
|
Juvenile Myelomonocytic Leukemia |
|
|
274 | (1) |
|
|
|
274 | (2) |
|
|
|
276 | (5) |
|
33 Storage Diseases of the Reticuloendothelial System |
|
|
281 | (8) |
|
|
|
|
|
|
|
281 | (1) |
|
|
|
281 | (1) |
|
|
|
282 | (1) |
|
|
|
282 | (1) |
|
|
|
282 | (1) |
|
|
|
282 | (4) |
|
|
|
286 | (1) |
|
|
|
286 | (1) |
|
Newborn Screening for Lysosomal Storage Disorders |
|
|
286 | (1) |
|
|
|
286 | (1) |
|
Principles of Treatment of Lysosomal Storage Disorders |
|
|
287 | (2) |
|
34 Molecular Biology Revolution in Hemato-Oncology---From Bench to the Bedside |
|
|
289 | (9) |
|
|
|
|
|
Primer of Molecular Biology |
|
|
289 | (2) |
|
|
|
291 | (1) |
|
Applications of Molecular Biology |
|
|
292 | (6) |
|
35 Hematopoietic Stem Cell Transplantation |
|
|
298 | (7) |
|
|
|
|
|
|
|
|
|
300 | (1) |
|
Graft Versus Host Disease |
|
|
300 | (2) |
|
Alternate Donor Transplantation |
|
|
302 | (3) |
|
36 Psychological Support of Chronic Blood Disorders |
|
|
305 | (4) |
|
|
|
|
|
|
|
Why is Psychological Support so Important? |
|
|
305 | (1) |
|
Communication by Doctors and Healthcare Professionals with Patients |
|
|
305 | (1) |
|
Coming to Terms with the Diagnosis |
|
|
306 | (1) |
|
|
|
306 | (1) |
|
Psychological Impact of Admissions to Hospital |
|
|
306 | (1) |
|
Adjustment in the Child with Chronic Blood Disorders |
|
|
306 | (1) |
|
|
|
307 | (1) |
|
|
|
307 | (1) |
|
|
|
307 | (1) |
|
|
|
307 | (2) |
|
37 Vascular Access and Specialized Techniques of Drug Delivery |
|
|
309 | (4) |
|
|
|
|
|
309 | (1) |
|
|
|
309 | (1) |
|
|
|
309 | (1) |
|
Catheter and Port Insertion Techniques |
|
|
309 | (1) |
|
Catheter Insertion Complications |
|
|
309 | (1) |
|
|
|
310 | (1) |
|
Technique of Catheter Insertion |
|
|
310 | (1) |
|
Problem Solving in Catheter Use |
|
|
311 | (1) |
|
|
|
311 | (1) |
|
Catheter-related Venous Thrombosis |
|
|
311 | (1) |
|
Catheter-related Infections |
|
|
312 | (1) |
| Index |
|
313 | |
